CEA-Targeting IgG1 Antibody Resisting Soluble Antigen Blocking
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapeutic approaches targeting CEA-bearing epithelial tumors are hindered by high levels of soluble CEA antigen in the plasma, which inhibit the effectiveness of anti-CEA antibody treatments by blocking tumor cell recognition and destruction, limiting their use to patients with low serum CEA levels.
Innovation Solution
Development of IgG1 antibodies specifically binding to human CEA with a unique variable region sequence that allows them to bind to both membrane-bound and soluble CEA, maintaining cytotoxic activity even in high concentrations of soluble CEA, thereby overcoming the inhibitory effect of soluble CEA antigen.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional anti-CEA antibodies are used to treat epithelial tumors, then tumor cell recognition and destruction is achieved, but high levels of soluble CEA antigen in plasma block the antibody-tumor cell interaction and inhibit therapeutic effectiveness
Solution Approach 1:
The patent applies parameter changes by modifying the antibody's binding characteristics through specific amino acid substitutions in the CDR regions. The antibodies are engineered to have altered affinity and specificity parameters, enabling them to distinguish between soluble and membrane-bound CEA. This allows the therapeutic antibody to maintain effectiveness by preferentially binding to tumor cell-associated CEA while having reduced interaction with soluble CEA in plasma.
Solution Approach 2:
The invention inverts the conventional approach by designing antibodies that are specifically designed to NOT bind to soluble CEA while maintaining strong binding to membrane-bound CEA on tumor cells. This inverse design strategy overcomes the blocking effect by making the antibody's therapeutic action dependent on its inability to bind soluble CEA, thereby preventing the harmful blocking interaction while preserving tumor cell recognition and destruction.
2Adaptability or versatility
If anti-CEA antibody treatments are administered to patients with high serum CEA levels, then the therapeutic potential is reduced, but limiting treatment to low CEA patients excludes those with progressive or malignant tumors who often have elevated CEA
Solution Approach 1:
The patent modifies the antibody parameters through rational design of the variable region, specifically engineering CDR sequences that confer differential binding characteristics. This allows the antibody to adapt to different CEA contexts (soluble vs. membrane-bound), enabling therapeutic use across a broader patient population including those with high serum CEA levels who have progressive or malignant tumors.
Solution Approach 2:
The invention creates a universal antibody platform that can function effectively across diverse clinical scenarios. The engineered antibodies possess multi-functionality by simultaneously achieving: (1) selective binding to tumor cell-associated CEA, (2) resistance to soluble CEA blocking, and (3) applicability to patients with varying CEA levels including those with progressive malignancies. This universality expands therapeutic accessibility without sacrificing effectiveness.
Data Source
Figure 1
Figure 2
Figure 3
AI summary
The present invention relates to pharmaceutical compositions for the treatment of an epithelial tumor in a human, said pharmaceutical composition comprising an IgG1 antibody specifically binding to human CEA, wherein the variable region of said IgG1 antibody comprises at least (i) a CDR-H1 having the amino acid sequence "SYWMH" and a CDR-H2 having the amino acid sequence "FIRNKANGGTTEYAASVKG" and a CDR-H3 having the amino acid sequence "DRGLRFYFDY" or (ii) a CDR-H 1 having the amino acid sequence "TYAMH" and a CDR-H2 having the amino acid sequence "LISNDGSNKYYADSVKG" and a CDR-H3 having the amino acid sequence "DRGLRFYFDY". Furthermore, processes for the production of said pharmaceutical compositions as well as medical/pharmaceutical uses for the IgG1 antibody molecules bearing specificities for the human CEA antigen are disclosed.